Literature DB >> 24111539

microRNA therapeutics in cardiovascular disease models.

Seema Dangwal1, Thomas Thum.   

Abstract

Cardiovascular diseases are a major cause of human morbidity and mortality, posing a high socioeconomic burden on the health sector worldwide. microRNAs (miRNAs) constitute a new class of unique molecular regulators involved in the pathophysiology of a wide range of disorders. Studies in the past decade have identified miRNA signatures of various cardiovascular disorders and successfully validated miRNA-based therapeutic options in various small and a few large experimental cardiovascular disease models. In these models, researchers manipulate the expression of miRNAs and downstream signaling cascades, aiming to prevent and cure cardiovascular disease. Here, we review and discuss the recent reports on the in vivo use of miRNA animal models and miRNA therapeutic development as well as provide an outlook for clinical applications in the near future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24111539     DOI: 10.1146/annurev-pharmtox-011613-135957

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  39 in total

Review 1.  Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China.

Authors:  Z W Pan; Y J Lu; B F Yang
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

Review 2.  The hippo pathway in heart development, regeneration, and diseases.

Authors:  Qi Zhou; Li Li; Bin Zhao; Kun-Liang Guan
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

3.  Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats.

Authors:  Jana P Ball; Maryam Syed; Rodrigo O Marañon; Michael E Hall; Roshan Kc; Jane F Reckelhoff; Licy L Yanes Cardozo; Damian G Romero
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

4.  Local Delivery of miR-21 Stabilizes Fibrous Caps in Vulnerable Atherosclerotic Lesions.

Authors:  Hong Jin; Daniel Y Li; Ekaterina Chernogubova; Changyan Sun; Albert Busch; Suzanne M Eken; Peter Saliba-Gustafsson; Hanna Winter; Greg Winski; Uwe Raaz; Isabel N Schellinger; Nancy Simon; Renate Hegenloh; Ljubica Perisic Matic; Maja Jagodic; Ewa Ehrenborg; Jaroslav Pelisek; Hans-Henning Eckstein; Ulf Hedin; Alexandra Backlund; Lars Maegdefessel
Journal:  Mol Ther       Date:  2018-01-31       Impact factor: 11.454

5.  Trim65: a cofactor for regulation of the microRNA pathway.

Authors:  Shitao Li; Lingyan Wang; Bishi Fu; Martin E Dorf
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

Review 6.  MicroRNAs in right ventricular (dys)function (2013 Grover Conference series).

Authors:  Thomas Thum; Sandor Batkai
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

Review 7.  Noncoding RNAs and myocardial fibrosis.

Authors:  Thomas Thum
Journal:  Nat Rev Cardiol       Date:  2014-09-09       Impact factor: 32.419

Review 8.  MicroRNAs as regulators of endothelial cell functions in cardiometabolic diseases.

Authors:  Elisa Araldi; Yajaira Suárez
Journal:  Biochim Biophys Acta       Date:  2016-01-26

Review 9.  Role of microRNA in metabolic shift during heart failure.

Authors:  Mark V Pinti; Quincy A Hathaway; John M Hollander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-10-14       Impact factor: 4.733

Review 10.  Impact of miRNA in Atherosclerosis.

Authors:  Yao Lu; Tanuja Thavarajah; Wenduo Gu; Jingjing Cai; Qingbo Xu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.